English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Shouichi Fujimoto, MD, First Department of Internal Medicine, Miyazaki Medical College 5200, Kihara, Kiyotake, Miyazaki 889-16 (Japan) Table 1. Time course change of UProE, UFR and UProE/UCreE following intravenous injection of rIL-2 at a dose of 70 × 104 JRU (mean ± SE, n = 8) Dear Sir, Interleukin-2 (IL-2) is a lymphokine modulating T cell function. Recombinant human IL-2 (rIL-2) has been used in adoptive im-munotherapy for malignancies. The major adverse effect of rIL-2 treatment is the vascular-leak syndrome, in which vascular permeability is increased, resulting in a leakage of proteinaceous fluids [1]. On the other hand, the production of a vascular permeability factor derived from T lymphocytes has been demonstrated in the minimal change ne-phrotic syndrome (MCNS) [2,3]. We reported a patient with nephrotic syndrome, which was considered to occur coincidently with rIL-2 treatment for malignant hemangioepithelio-ma, and where rIL-2 might cause MCNS [4]. In order to clarify whether rIL-2 might be involved in proteinuria associated with a reduction in anionic sites of the glomerular basement membrane (GBM), we studied the acute and chronic effects of rIL-2 in rats. Wistar-Kyoto rats (WKY) were cannulat-ed in the right jugular vein and the bladder, and isotonic saline (20 μl/min) was infused throughout the experiment. Saline or several doses of rIL-2 (Shionogi Pharmaceutical Co., Osaka, Japan) were injected via the jugular vein. Urine samples were collected every 5-10 min. Urine flow rate (UFR), urinary protein excretion (UProE) and urinary creatinine excretion (UCreE) were measured. For the histological study, 0.5% of polyethyleneimine (PEI) was injected as a cationic probe 10 min after the injection of rIL-2 or isotonic saline. UProE did not change after the rIL-2 infusion at doses of 3.5-35 × 104 JRU as compared to the level before injection. However, the injection of rIL-2 at a dose of 70 × 104 JRU caused an increase in UProE by 3-fold in comparison with the control phase and a concomitant increase in UFR by 5-fold. A UProE/UCreE ratio was not different before and after the injection of rIL-2 (table 1). Ten minutes later, these modifications returned to the levels before injection. A dose-dependent increase in UProE was no longer evident in a dose of 140 × 104 JRU of rIL-2. Anionic sites were stained regularly with PEI on the lamina rara externa

Recombinant lnterleukin-2 Alone Did Not Induce Proteinuria with Changes in Anionic Sites of the Glomerular Basement Membrane in Rats